002566.SZ
益盛药业
SZSE · Healthcare · C 制造业 · CN
CNY 6.74
−0.74%Year over year
Reported trailing growth
- Revenue
- +5.2%
- EBITDA
- —
- EBIT
- -27.1%
- EPS
- -22.4%
- Free cash flow
- +264.4%
- Operating cash flow
- +183.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -8.3%
- EBITDA
- -21.1%
- EBIT
- -32.7%
- Net income
- -29.6%
- EPS
- -29.6%
- Free cash flow
- -6.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026